Other Information.
−Removed: Trading Plans or Rule 10b5-1 Trading Plans
−Removed: During the quarter ended September 30, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
−Removed: Date of Adoption/
−Removed: Type of Trading Arrangement
−Removed: Expiration Date
−Removed: Total Shares of Common Stock to be Sold***
−Removed: Non-Rule 10b5-1**
−Removed: July 30, 2024 (1)
−Removed: August 16, 2024
−Removed: * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
−Removed: ** "Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
−Removed: *** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 trading arrangement.
−Removed: The number of shares to be sold was dependent on the satisfaction of certain conditions as set forth in the written plan.
−Removed: (1) Represents the termination of a written plan originally adopted on May 16, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Incorporated by Reference
+Added: Sales Agreement between Olema Pharmaceuticals, Inc.
+Added: and TD Securities (USA) LLC, dated January 6, 2025
Amended and Restated Certificate of Incorporation.
Amended and Restated Bylaws.
+Added: Form of Exchange Warrant
+Added: Olema Pharmaceuticals, Inc.
+Added: Amended and Restated Non-Employee Director Compensation Policy
+Added: Offer Letter by and between the Registrant and Shawnte Mitchell, dated January 7, 2025
Certification of Chief Executive Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
6 unchanged sentences
* Filed herewith.
+Added: # Indicates management contract or compensatory plan or arrangement
The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.
2 unchanged sentences
Olema Pharmaceuticals, Inc.
−Removed: November 12, 2024
/s/ Sean Bohen, M.D., Ph.D.
2 unchanged sentences
( Principal Executive Officer )
−Removed: November 12, 2024
/s/ Shane Kovacs
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.